8.00
-0.60 (-6.98%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bullish |
| Biotechnology (Global) | Bearish | Bullish | |
| Stock | Arcutis Biotherapeutics, Inc. | Bullish | Bearish |
Analyst Consensus
2 Buy, 1 Hold
Avg. Price @ Call: 9.55
|
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| 52 Weeks Range |
1.76 - 15.12
|
|
| Price Target Range | ||
| High | 18.00 (Mizuho, 125.00%) | Buy |
| 18.00 (Needham, 125.00%) | Buy | |
| Median | 16.00 (100.00%) | |
| Low | 11.00 (Goldman Sachs, 37.50%) | Hold |
| Average | 14.67 (83.34%) | |
| Total | 2 Buy, 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 15 May 2024 | 18.00 (125.00%) | Buy | 9.13 |
| 28 Feb 2024 | 17.00 (112.50%) | Buy | 10.41 | |
| Needham | 15 May 2024 | 18.00 (125.00%) | Buy | 9.13 |
| 12 Apr 2024 | 16.00 (100.00%) | Buy | 10.20 | |
| Goldman Sachs | 28 Feb 2024 | 11.00 (37.50%) | Hold | 10.41 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |